SEC Comment Letter for Solid Biosciences Inc. (SLDB) (CIK 0001707502) (SLDB) — Mar 14, 2019
Solid Biosciences Inc. (SLDB) (CIK 0001707502)
Date: March 14, 2019 · CIK: 0001707502 · Accession: 0000000000-19-004753
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230228
Letter
March 14, 2019 Ilan Ganot Chief Executive Officer Solid Biosciences Inc. 141 Portland Street, Fifth Floor Cambridge, MA 02139 Re:Solid Biosciences Inc. Registration Statement on Form S-3 Filed March 13, 2019 File No. 333-230228 Dear Mr. Ganot: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Donald Field at 202-551-3680 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
March 14, 2019
Ilan Ganot
Chief Executive Officer
Solid Biosciences Inc.
141 Portland Street, Fifth Floor
Cambridge, MA 02139
Re:Solid Biosciences Inc.
Registration Statement on Form S-3
Filed March 13, 2019
File No. 333-230228
Dear Mr. Ganot:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Donald Field at 202-551-3680 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance